Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma
暂无分享,去创建一个
C. Tournigand | C. Lepage | A. Bertaut | L. Bengrine | J. Vincent | F. Ghiringhelli | C. Canivet | J. Adnet | J. Cros | J. Bachet | D. Piquemal | A. Gagnaire | I. Baumgaertner | F. Pierrat | B. Bournet | E. Kempf | P. Afchain | S. Manfredi | F. Noguier | R. Bruno | I. Trouilloud | A. Drouillard | E. Rederstorff | L. Evesque | É. Soularue | N. Loconte | A. Hennequin | A. Saint | Amelia Gamez | Erwan Petit | Daniel Lopez Trabada Ataz | A. Gamez
[1] D. Principe. Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition , 2022, Cancers.
[2] J. Iovanna,et al. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer , 2021, Translational oncology.
[3] S. Melo,et al. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review) , 2021, International journal of oncology.
[4] G. Xiao,et al. MicroRNAs in Pancreatic Cancer and Chemoresistance , 2021, Pancreas.
[5] M. Scartozzi,et al. BRCA-mutant pancreatic ductal adenocarcinoma , 2021, British Journal of Cancer.
[6] J. Rabinowitz,et al. Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer , 2021, International journal of biological sciences.
[7] Quanbo Zhou,et al. Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and ABCC1 transactivation , 2021, Cell Death & Disease.
[8] A. Carrier,et al. Targeting Redox Metabolism in Pancreatic Cancer , 2021, International journal of molecular sciences.
[9] J. Cros,et al. Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer , 2020, Cancers.
[10] P. Philip,et al. Surgical Outcome Results From SWOG S1505 , 2020, Annals of surgery.
[11] P. Laurent-Puig,et al. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma , 2020, Clinical Cancer Research.
[12] P. Laurent-Puig,et al. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. , 2020, Cancer treatment reviews.
[13] E. O’Reilly,et al. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma , 2020, Drugs.
[14] J. Mackey,et al. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status , 2019, Cancers.
[15] Joon-Oh Park,et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.
[16] M. Honda,et al. Development of novel diagnostic system for pancreatic cancer, including early stages, measuring mRNA of whole blood cells , 2019, Cancer science.
[17] S. Truant,et al. A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort , 2018, BMC Cancer.
[18] E. Giovannetti,et al. Multidrug‐resistant transporter expression does not always result in drug resistance , 2018, Cancer science.
[19] Yuk Ting Ma,et al. Gemcitabine-Induced Cardiotoxicity in Patients Receiving Adjuvant Chemotherapy for Pancreatic Cancer: A Case Series , 2018, Case Reports in Oncology.
[20] J. Kleeff,et al. Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells , 2017, Cancers.
[21] P. Singh,et al. De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. , 2017, Cancer research.
[22] N. Schultz,et al. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype , 2017, Clinical Cancer Research.
[23] Valérie Taly,et al. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker , 2016, Clinical Cancer Research.
[24] J. Winter,et al. Pancreatic Cancer: A Review. , 2016, Gastroenterology clinics of North America.
[25] B. Melichar,et al. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[27] C. la Vecchia,et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] Isabelle Salmon,et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. , 2012, Gastroenterology.
[29] U. Ballehaninna,et al. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. , 2012, Journal of gastrointestinal oncology.
[30] D. Aust,et al. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[32] L. Ellis,et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.